July 28 (Reuters) - Targacept Inc said it was stopping development of a drug to treat overactive bladder after it failed to show significant reduction in incontinence in a mid-stage study.
The company's shares fell 32 percent in extended trading after it cancelled its third drug development program in eight months and said it may change the direction of its research.
Also read: Caterpillar Says Sales Woes Could Linger
20:52 After earning crush, Tesla expected to unveil 'solar roof', integrated home battery36
16:01 Danish CV90s to receive BAE battle management systems11
12:23 Lockheed Martin's quarterly profit handily beats estimates24
11:41 Caterpillar earnings: 85 cents per share, vs expected EPS of 76 cents19